Peer-reviewed veterinary case report
New antibody treatment tested for advanced cancer in dogs
By Igase, Masaya et al.·Published in Scientific reports·2020·The United Graduate School of Veterinary Medicine, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs.
- Species:
- dog
Plain-English summary
A dog with advanced oral malignant melanoma, a serious and aggressive type of cancer, was treated with a new therapeutic antibody designed to boost the immune response against the tumor. This treatment, which targets a specific protein (PD-1) on immune cells, showed promise in helping the dog's body fight the cancer. The study found that the antibody was relatively safe and effective, suggesting it could be a valuable option for dogs suffering from advanced cancers. While more research is needed, this could lead to better treatment options for pets with similar conditions.
People also search for: dog melanoma treatment · advanced cancer in dogs · PD-1 antibody for dogs · canine cancer immunotherapy
Abstract
Inhibition of programmed death 1 (PD-1), expressed on activated T cells, can break through immune resistance and elicit durable responses in human melanoma as well as other types of cancers. Canine oral malignant melanoma is one of the most aggressive tumors bearing poor prognosis due to its high metastatic potency. However, there are few effective treatments for the advanced stages of melanoma in veterinary medicine. Only one previous study indicated the potential of the immune checkpoint inhibitor, anti-canine PD-L1 therapeutic antibody in dogs, and no anti-canine PD-1 therapeutic antibodies are currently available. Here, we developed two therapeutic antibodies, rat-dog chimeric and caninized anti-canine PD-1 monoclonal antibodies and evaluated in vitro functionality for these antibodies. Moreover, we conducted a pilot study to determine their safety profiles and clinical efficacy in spontaneously occurring canine cancers. In conclusion, the anti-canine PD-1 monoclonal antibody was relatively safe and effective in dogs with advanced oral malignant melanoma and other cancers. Thus, our study suggests that PD-1 blockade may be an attractive treatment option in canine cancers.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33110170/